Home › Funds › Carmignac Gestion › VRTX
Carmignac Gestion position in VRTX
VERTEX PHARMACEUTICALS INC · Health Care
Carmignac Gestion reported holding 163,285 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$85.4M, representing 1.36% of its reported portfolio and ranking #23 among its reported holdings. Carmignac Gestion has disclosed VRTX holdings in 10 of the last 10 reported quarters, going back to Q2 2024.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Carmignac Gestion's VRTX position evolved
Carmignac Gestion first disclosed a stake in VRTX in Q2 2024 at 185,249 shares (US$86.8M). The position peaked in Q2 2025 at 227,296 shares, worth US$101.2M. Across 10 filings, Carmignac Gestion increased the stake 4 time(s), trimmed it 4 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 163,285 shares valued at US$85.4M. Notable position changes include a 36% trim in Q1 2025 (shares fell 8% over the following quarter), a 79% increase in Q2 2025 (shares fell 12% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2024 | 185.25K | $86.85M | New |
| Q3 2024 | 210.52K | $97.89M | Add |
| Q4 2024 | 197.47K | $79.49M | Reduce |
| Q1 2025 | 126.95K | $61.61M | Reduce |
| Q2 2025 | 227.30K | $101.16M | Add |
| Q3 2025 | 187.54K | $73.46M | Reduce |
| Q4 2025 | 191.57K | $86.85M | Add |
| Q1 2026 | 148.20K | $66.16M | Reduce |
| Q2 2026 | 163.04K | $81.00M | Add |
| Q3 2026 | 163.28K | $85.39M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About VRTX and 13F data
VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 32 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$13.58B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding VRTX
- Capital World Investors 25.97M sh · $13.58B · Q3 2026
- Capital World Investors 26.12M sh · $12.97B · Q2 2026
- Capital Research Global Investors 19.49M sh · $9.68B · Q2 2026
- Capital Research Global Investors 17.81M sh · $9.31B · Q3 2026
- Invesco Ltd 8.28M sh · $4.33B · Q3 2026
- Capital International Investors 5.06M sh · $2.65B · Q3 2026
- Franklin Resources 4.46M sh · $2.45B · Q3 2026
- LOOMIS SAYLES & CO L P 3.62M sh · $1.89B · Q3 2026
- JENNISON ASSOCIATES LLC 3.00M sh · $1.49B · Q2 2026
- ALLIANCEBERNSTEIN L.P. 3.02M sh · $1.35B · Q2 2026
- VICTORY CAPITAL MANAGEMENT INC 2.56M sh · $1.34B · Q3 2026
- Janus Henderson Group 2.13M sh · $951.79M · Q1 2026
More on Carmignac Gestion
FAQ
How long has Carmignac Gestion held VRTX?
Carmignac Gestion has disclosed VRTX holdings in 10 of the last 10 reported quarters, going back to Q2 2024.
What is Carmignac Gestion's current position in VRTX?
As of Q3 2026, Carmignac Gestion holds 163.28K shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $85.39M, representing 1.36% of its reported portfolio and ranking #23.
Has Carmignac Gestion been buying or selling VRTX?
In the latest 13F filing (Q3 2026), Carmignac Gestion held unchanged its position in VRTX. The position peaked in Q2 2025 at 227.30K shares.
Which other funds hold VRTX?
Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 32 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.